1416: Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.
Lower baseline prostate-specific antigen is associated with a greater overall
survival benefit from sipuleucel-T in the Immunotherapy for Prostate
Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013 Jun;81(6):1297-302. doi:
10.1016/j.urology.2013.01.061. Epub 2013 Apr 9. PubMed PMID: 23582482.


1417: Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen
presenting cells for the treatment of androgen independent prostate cancer. World
J Urol. 2005 Feb;23(1):47-9. Epub 2005 Jan 13. PubMed PMID: 15647927.


1418: Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical bacillus
Calmette-Guerin for the treatment of superficial transitional cell carcinoma of
the prostatic urethra in association with carcinoma of the bladder. J Urol. 1995 
Jan;153(1):53-6. PubMed PMID: 7966790.